Pictet Asset Management
CRSP icon

Pictet Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Pictet Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.99M Sell
142,213
-11,794
-8% -$622K 0.01% 721
2026
Q1 		$6.87M Sell
154,007
-13,457
-8% -$710K 0.01% 729
2025
Q4 		$9.02M Sell
167,464
-25,129
-13% -$1.5M 0.01% 695
2025
Q3 		$12.3M Sell
192,593
-43,327
-18% -$2.49M 0.01% 626
2025
Q2 		$11.2M Sell
235,920
-10,166
-4% -$393K 0.01% 628
2025
Q1 		$9.07M Sell
246,086
-26,618
-10% -$1.13M 0.01% 685
2024
Q4 		$10.7M Buy
272,704
+22,414
+9% +$1.06M 0.01% 648
2024
Q3 		$11.8M Buy
250,290
+59,882
+31% +$3.04M 0.01% 609
2024
Q2 		$10.3M Sell
190,408
-130,115
-41% -$7.53M 0.01% 621
2024
Q1 		$22.2M Buy
320,523
+311,849
+3,595% +$22.3M 0.02% 475
2023
Q4 		$543K Hold
8,674
– – ﹤0.01% 1224
2023
Q3 		$394K Buy
+8,674
New +$448K ﹤0.01% 1339

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Pictet Asset Management's CRSP Position: Q2 2026 in Review

Pictet Asset Management reduced its CRISPR Therapeutics (CRSP) stake by 7.7% in Q2 2026, selling an estimated $622K and leaving 142,213 shares worth $7.99M. The position accounts for 0.01% of the portfolio, ranked #721.

Pictet Asset Management first reported a position in CRSP in Q3 2023 and has held it in 12 quarters since. The position peaked at $22.2M in Q1 2024. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Pictet Asset Management held 142,213 shares of CRISPR Therapeutics worth $7.99M as of Q2 2026.
  • Pictet Asset Management sold 11,794 CRISPR Therapeutics shares in Q2 2026, an estimated $622K.
  • CRISPR Therapeutics made up 0.01% of Pictet Asset Management's portfolio in Q2 2026, its #721 holding.
  • Pictet Asset Management first reported a position in CRISPR Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Pictet Asset Management's CRISPR Therapeutics position peaked at $22.2M in Q1 2024.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.